|

A2B395 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Tmod CAR T-cell Therapy

Pipeline

Phase 1/2: 1

Top Sponsors

  • A2 Biotherapeutics Inc.1

Indications

  • Non-Small-Cell Lung1
  • TNBC1
  • RCC1
  • NSCLC (Non-small Cell Lung Cancer)1
  • Head and Neck Squamous Cell Cancer1

Gilbert, Arizona1 trial

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Banner MD Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.